Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2019 08:00 ET | Source: Synthorx, Inc.

Synthorx to Present at Upcoming Investor Conferences

SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
November 05, 2019 16:05 ET | Source: Synthorx, Inc.

Synthorx Reports Third Quarter Financial Results

SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (Nasdaq: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
November 05, 2019 08:00 ET | Source: Synthorx, Inc.

Synthorx to Present THOR-809 Data at the American College of Rheumatology (ACR) Annual Meeting

SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
October 29, 2019 16:05 ET | Source: Synthorx, Inc.

Synthorx to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
September 23, 2019 08:00 ET | Source: Synthorx, Inc.

Synthorx to Present at the European Society for Medical Oncology (ESMO) 2019 Congress

SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
September 09, 2019 08:00 ET | Source: Synthorx, Inc.

Synthorx to Present at the 2019 World Congress of Inflammation

SAN DIEGO, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
August 29, 2019 16:05 ET | Source: Synthorx, Inc.

Synthorx to Present at H.C. Wainwright 21st Annual Global Investment Conference

SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
August 01, 2019 16:05 ET | Source: Synthorx, Inc.

Synthorx Reports Second Quarter Financial Results

SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (Nasdaq: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
July 24, 2019 08:00 ET | Source: Synthorx, Inc.

Synthorx Initiates Patient Dosing in Australia and Announces Clearance of IND in the U.S. for Lead Immuno-oncology Product Candidate, THOR-707

SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, announced...
May 29, 2019 16:10 ET | Source: Synthorx, Inc.

Synthorx to Present at Jefferies 2019 Healthcare Conference

SAN DIEGO, May 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop...

Next Page keyboard_arrow_right

Latest News and Press Releases

Search Results

Search Filters